MedTrace Logo

Urinary Biomarker Study With Sulindac and Difluoromethylornithine

NCT01636128 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2014-07-30

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of 2 drugs (sulindac and Difluoromethylornithine (DFMO)) either alone or in combination on biomarkers found in urine.

Conditions

  • Focus of Study: Drug Response Biomarkers, Chemoprevention, Neoplasms

Interventions

DRUG

difluoromethylornithine

500 mg oral for 14 days, combined with sulindac for 15 days

DRUG

Sulindac

150 mg oral for 15 days, combined with DFMO for 14 days

Sponsors & Collaborators

  • University of Arizona

    collaborator OTHER

  • Cancer Prevention Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2016-03-31
Completion
2016-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01636128 on ClinicalTrials.gov